• Home
  • Search Results
  • Homozygous inactivating mutation in NANOS3 in two sisters with primary ovarian insufficiency.

Homozygous inactivating mutation in NANOS3 in two sisters with primary ovarian insufficiency.

BioMed research international (2014-07-24)
Mariza G Santos, Aline Z Machado, Conceição N Martins, Sorahia Domenice, Elaine M F Costa, Mirian Y Nishi, Bruno Ferraz-de-Souza, Soraia A C Jorge, Carlos A Pereira, Fernanda C Soardi, Maricilda P de Mello, Andrea T Maciel-Guerra, Gil Guerra-Junior, Berenice B Mendonca
ABSTRACT

Despite the increasing understanding of female reproduction, the molecular diagnosis of primary ovarian insufficiency (POI) is seldom obtained. The RNA-binding protein NANOS3 poses as an interesting candidate gene for POI since members of the Nanos family have an evolutionarily conserved function in germ cell development and maintenance by repressing apoptosis. We performed mutational analysis of NANOS3 in a cohort of 85 Brazilian women with familial or isolated POI, presenting with primary or secondary amenorrhea, and in ethnically-matched control women. A homozygous p.Glu120Lys mutation in NANOS3 was identified in two sisters with primary amenorrhea. The substituted amino acid is located within the second C2HC motif in the conserved zinc finger domain of NANOS3 and in silico molecular modelling suggests destabilization of protein-RNA interaction. In vitro analyses of apoptosis through flow cytometry and confocal microscopy show that NANOS3 capacity to prevent apoptosis was impaired by this mutation. The identification of an inactivating missense mutation in NANOS3 suggests a mechanism for POI involving increased primordial germ cells (PGCs) apoptosis during embryonic cell migration and highlights the importance of NANOS proteins in human ovarian biology.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium butyrate, ≥98.5% (GC)
Sigma-Aldrich
Sodium butyrate, 98%
Supelco
Sodium butyrate, certified reference material, TraceCERT®